InvestorsHub Logo

caddiedad

04/24/22 1:11 PM

#375414 RE: rosemountbomber #375413

Understood…I remember a post in 2Q ‘20 describing how a covid trial might just end up being a possible bonus in the Vascepa anti inflammatory portfolio. The time spent in Mitigate has been plenty and if more data scrutiny is/was needed, then that’s a good thing.

Whalatane

04/24/22 1:51 PM

#375417 RE: rosemountbomber #375413

U get a pass … English is your second language isn’t it. :—)
Kiwi